ZYME News and Press, Zymeworks Inc. From 05/02/24

2024-05-02 20:04:10 ET Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript May 02, 2024 04:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Ken Galbraith - Chair and CEO Paul Moore - Chief Scientific Officer Conference Call Pa...

2024-05-02 16:47:22 ET More on Zymeworks Zymeworks Q1 2024 Earnings Preview Zymeworks shares sink after company removes CFO Christopher Astle Read the full article on Seeking Alpha For further details see: Zymeworks files automatic mixed securities shelf

2024-05-02 16:27:08 ET More on Zymeworks Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript Zymeworks Q1 2024 Earnings P...

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administ...

2024-04-18 15:06:45 ET Summary Zymeworks is a biotechnology company that develops innovative therapies for difficult-to-treat cancers and serious conditions. The company's flagship drug, Zanidatamab, is in phase 3 clinical trials and has significant market potential for biliary tr...

2024-04-18 13:26:38 ET Summary Jazz Pharmaceuticals plc has a neuroscience franchise that is led by Xywav, which has replaced Xyrem as the top treatment for narcolepsy. The company's narcolepsy franchise is facing competition from Avadel Pharmaceuticals' Lumryz, but Jazz is defend...

2024-04-15 22:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manag...

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced five prese...

2024-04-06 01:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...